亚太地区阿片类药物市场预测至 2030 年 - 区域分析 - 按产品（速释短效阿片类药物和缓释长效阿片类药物）、应用（疼痛管理、麻醉、腹泻抑制、咳嗽抑制、脱瘾等）、给药途径（口服、注射和透皮贴剂）和分销渠道（医院药房和零售药房）

Historic Data: 2020-2021   |   Base Year: 2022   |   Forecast Period: 2023-2030

No. of Pages: 93    |    Report Code: BMIRE00030983    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
Asia Pacific Opioids Market
Free Sample Buy Now
2022 年亚太阿片类药物市场价值为 24.0624 亿美元，预计到 2030 年将达到 30.9177 亿美元；预计 2022 年至 2030 年的复合年增长率为 3.2%。

慢性疼痛发病率飙升推动亚太阿片类药物市场发展

心血管疾病、癌症、肌肉骨骼疾病和神经血管疾病等慢性疾病会降低免疫力，严重影响人体健康。此外，许多患有这些疾病的患者都会经历慢性疼痛。上述疾病在成人和老年人群中最常见。然而，这些疾病的病例在儿童中也明显增加。慢性疼痛在运动员、运动员和过去受过伤的人中也很常见。根据美国国家生物技术信息中心 (NCBI) 发表的一项研究，全球有 20% 的成年人患有疼痛，每年有 10% 的人新诊断出患有慢性疼痛。尽管疼痛影响所有人群，无论性别、种族/民族、收入、年龄或地理位置如何，但它在世界各地的分布并不均匀。处方阿片类药物，包括氢可酮、羟可酮和吗啡，是有效的止痛药，用于治疗由受伤、手术和癌症、关节炎等健康状况引起的疼痛。

阿片类药物处方量的增加可以归因于保险报销计划，这些计划鼓励人们使用阿片类药物而不是替代性疼痛治疗，成本结构鼓励更有效的护理，以及将患者满意度与有效疼痛管理相结合的评估。因此，由于阿片类药物在疼痛管理方面的优势，慢性病患者的需求正在上升。

亚太阿片类药物市场概览

据估计，中国患有绝症的老年人口不断增加，将大大增加对阿片类药物的需求。根据世界卫生组织 (WHO) 的数据，中国是老龄人口增长最快的国家之一。根据同一来源，2019 年 60 岁及以上人口为 2.54 亿，65 岁及以上人口为 1.76 亿。此外，由于预期寿命增加和出生率下降，预计到 2040 年中国 60 岁及以上人口将占总人口的约 28%（4.02 亿人）。老年人口更容易患上与疼痛相关的慢性健康疾病，如关节炎、背痛、癌症等。在这种情况下，阿片类药物用于治疗老年人的慢性疼痛，这极大地影响了中国亚太阿片类药物市场的增长。在中国，患有严重病理性疼痛的新癌症患者数量显著增加。根据 2020 年发表的一项研究“医生继续医学教育对中国癌症疼痛治疗质量的影响”，中国政府鼓励使用阿片类止痛药治疗中度至重度癌症疼痛，这种药物在全国三级医院和二级医院广泛使用。由于阿片类药物是三步止痛阶梯的重要组成部分，并被推荐用于缓解中度和重度癌症疼痛，因此提高对此类疾病和相关治疗的认识可以改善癌症疼痛的治疗方案。

亚太阿片类药物市场收入和预测到 2030 年（百万美元）

亚太阿片类药物市场细分

亚太阿片类药物市场分为产品、应用、给药途径、分销渠道和国家。

根据产品，亚太阿片类药物市场分为速释短效阿片类药物和缓释长效阿片类药物。速释短效阿片类药物部分在 2022 年占据了更大的市场份额。速释短效阿片类药物进一步细分为羟可酮、氢可酮、曲马多、可待因、丙氧芬等。缓释长效阿片类药物进一步细分为羟可酮、芬太尼、吗啡、美沙酮等。

在应用方面，亚太阿片类药物市场分为疼痛管理、麻醉、腹泻抑制、咳嗽抑制、脱瘾等。疼痛管理部分在 2022 年占据了最大的市场份额。

按给药途径，亚太阿片类药物市场分为口服、注射和透皮贴剂。口服药物在 2022 年占据了最大的市场份额。

按分销渠道划分，亚太阿片类药物市场分为医院药房和零售药房。2022 年，医院药房部分占据了更大的市场份额。

按国家划分，亚太阿片类药物市场分为中国、日本、印度、韩国、澳大利亚和亚太其他地区。2022 年，中国占据了亚太阿片类药物市场份额的主导地位。

Endo International plc、Mallinckrodt Plc、Neuraxpharm Pharmaceuticals SL、Mayne Pharma Group Ltd、Rusan Pharma Ltd 和 Teva Pharmaceutical Industries Ltd 是亚太阿片类药物市场的一些领先公司。

Asia Pacific Opioids Strategic Insights

Strategic insights for Asia Pacific Opioids involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/asia-pacific-opioids-market-strategic-framework.webp
Get more information on this report

Asia Pacific Opioids Report Scope

Report Attribute Details
Market size in 2022 US$ 2,406.24 Million
Market Size by 2030 US$ 3,091.77 Million
Global CAGR (2022 - 2030) 3.2%
Historical Data 2020-2021
Forecast period 2023-2030
Segments Covered By 产品
  • 速释短效阿片类药物
  • 缓释长效阿片类药物
By 应用
  • 疼痛管理
  • 麻醉
  • 止泻
  • 止咳
  • 戒毒
By 给药途径
  • 口服
  • 注射
  • 透皮贴剂
By 分销渠道
  • 医院药房
  • 零售药房
Regions and Countries Covered 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 亚太其他地区
Market leaders and key company profiles
  • Endo International plc
  • Mallinckrodt Plc
  • Neuraxpharm Pharmaceuticals SL
  • Mayne Pharma Group Ltd
  • Rusan Pharma Ltd
  • Teva Pharmaceutical Industries Ltd
    		•
    Get more information on this report

    Asia Pacific Opioids Regional Insights

    The regional scope of Asia Pacific Opioids refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/asia-pacific-opioids-market-geography.webp
    Get more information on this report
    Identical Market Reports with other Region/Countries

    The List of Companies - Asia Pacific Opioids Market

    1. Endo International plc
    2. Mallinckrodt Plc
    3. Neuraxpharm Pharmaceuticals SL
    4. Mayne Pharma Group Ltd
    5. Rusan Pharma Ltd
    6. Teva Pharmaceutical Industries Ltd
    Frequently Asked Questions
    How big is the Asia Pacific Opioids Market?

    The Asia Pacific Opioids Market is valued at US$ 2,406.24 Million in 2022, it is projected to reach US$ 3,091.77 Million by 2030.

    What is the CAGR for Asia Pacific Opioids Market by (2022 - 2030)?

    As per our report Asia Pacific Opioids Market, the market size is valued at US$ 2,406.24 Million in 2022, projecting it to reach US$ 3,091.77 Million by 2030. This translates to a CAGR of approximately 3.2% during the forecast period.

    What segments are covered in this report?

    The Asia Pacific Opioids Market report typically cover these key segments-

  • 产品 (速释短效阿片类药物, 缓释长效阿片类药物)
  • 应用 (疼痛管理, 麻醉, 止泻, 止咳, 戒毒)
  • 给药途径 (口服, 注射, 透皮贴剂)

    • What is the historic period, base year, and forecast period taken for Asia Pacific Opioids Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Opioids Market report:

  • Historic Period : 2020-2021
  • Base Year : 2022
  • Forecast Period : 2023-2030
    • Who are the major players in Asia Pacific Opioids Market?

    The Asia Pacific Opioids Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Endo International plc
  • Mallinckrodt Plc
  • Neuraxpharm Pharmaceuticals SL
  • Mayne Pharma Group Ltd
  • Rusan Pharma Ltd
  • Teva Pharmaceutical Industries Ltd
    • Who should buy this report?

    The Asia Pacific Opioids Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Asia Pacific Opioids Market value chain can benefit from the information contained in a comprehensive market report.

    asia-pacific-opioids-market